The Biopharma Division of the New Jersey Innovation Institute (NJII), an NJIT corporation, has launched BioCentriq as its cell and gene therapy production and manufacturing center. BioCentriq is a process development and clinical manufacturing facility for cell and gene therapies located in Newark, NJ, and the first of its kind to be located on a university campus in the U.S.

The Biopharma Division has initiated the qualification and validation process for the BioCentriq facility and its equipment. This GMP facility is located at NJIT’s Life Sciences and Engineering center and features two GMP suites. The GMP suites are expected to complete their qualification and validation and be operational this summer. BioCentriq also offers a process development center, currently located at the Rutgers Medical School in Newark, which has been supporting projects since late 2019.

“BioCentriq will help bring innovative and novel therapies to clinical trials, providing a venue for established companies and start-ups alike. It is also a unique training ground for the workforce of the future,” said Dr. Haro Hartounian, SVP and General Manager of Biopharma at NJII. “We are grateful to all our partners who have supported us financially and with in-kind donations of equipment and supplies, as well as the industry leaders who serve on our advisory board and lend us their expertise.”

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of PharmaSources.com,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@imsinoexpo.com.